Adjuvant Development Program in the context of vaccines to protect against Y. pestis and Shigella.

University Of Maryland Baltimore, Baltimore MD

Investigators

Abstract

This contract supports the development of an adjuvant through immunological characterization studies and compound optimization, up to and including IND-enabling studies. The main emphasis will be on testing and further development of the adjuvant for human licensure as a component of a licensed or investigational vaccine to protect against one or more non-HIV disease pathogens relevant to human disease.